E3-Ubiquitin-Protein-Ligase-XIAP-(Baculoviral-IAP-Repeat-Containing-Protein-4-or-IAP-Like-Protein-or-Inhibitor-Of-Apoptosis-Protein-3-or-X-Linked-Inhibitor-Of-Apoptosis-Protein-or-XIAP-or-EC-6.3.2.)-Pipeline-Review-H2-2017

E3-Ubiquitin-Protein-Ligase-XIAP-(Baculoviral-IAP-Repeat-Containing-Protein-4-or-IAP-Like-Protein-or-Inhibitor-Of-Apoptosis-Protein-3-or-X-Linked-Inhibitor-Of-Apoptosis-Protein-or-XIAP-or-EC-6.3.2.)-Pipeline-Review-H2-2017


  • Products Id :- GMDHC0984TDB
  • |
  • Pages: 70
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Pipeline Review, H2 2017

Summary

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-E3 Ubiquitin-Protein Ligase X-linked inhibitor of apoptosis protein (XIAP) also known as inhibitor of apoptosis protein 3 (IAP3) and baculoviral IAP repeat-containing protein 4 (BIRC4) is a protein that stops apoptotic cell death. It modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. It acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. It inactivates CASP9 by keeping it in inactive state. It regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. It acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs).

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 4 and 7 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Breast Cancer, Ovarian Cancer, Solid Tumor, Epithelial Ovarian Cancer, Head And Neck Cancer, Melanoma, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Colorectal Cancer, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Lung Cancer, Lymphoma, Malignant Mesothelioma, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Pancreatic Cancer, Myelofibrosis, Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer.

The latest report E3 Ubiquitin Protein Ligase XIAP-Pipeline Review, H2 2017, outlays comprehensive information on the E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)

The report reviews E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects

The report assesses E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Overview

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Companies Involved in Therapeutics Development

Adamed Sp z oo

Astex Pharmaceuticals Inc

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd

Novartis AG

Noxopharm Ltd

Takeda Pharmaceutical Company Ltd

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Drug Profiles

AD-O53.2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASTX-660-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Debio-1143-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-118-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idronoxil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCL-161-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-1200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Inhibit XIAP for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit XIAP and IAP for Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit XIAP for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit XIAP for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit XIAP for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-3256336-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Dormant Products

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Discontinued Products

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)-Product Development Milestones

Featured News & Press Releases

Jul 06, 2017: Noxopharm provides update on NOX66 Clinical Trial Program

Jun 19, 2017: Idronoxil Data Provides Hope To Treat Secondary Brain Cancers

Jun 15, 2017: Debiopharm International Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN English

Jun 05, 2017: Nox66 Confirmed Non-toxic Trial Cleared for Full Enrolment

May 30, 2017: Noxopharm: Release Of New Corporate Presentation

May 29, 2017: St Vincents Hospital Sydney Cancer Study To Commence With Nox66 Radiotherapy

May 24, 2017: Noxopharm Makes Strategic Commitment To Treatment Of Rare Cancers

Apr 10, 2017: Noxopharm Files Patent Application on 'Smart'-Idronoxil

Mar 27, 2017: Noxopharm and Monash University Collaboration Receives Federal Grant

Mar 23, 2017: Debiopharm International Uses Cutting-Edge ClinTrialApp Mobile Application From ClinOne in Clinical Study

Mar 08, 2017: Mayo Clinic researchers identify therapy

Nov 23, 2016: Breakthrough In Delivering Idronoxil Into Brain

Nov 17, 2016: Medical Advisors Appointed To Support Extensive Clinical Program

Aug 22, 2016: Noxopharm To Initiate Radio Therapy Clinical Studies

Aug 10, 2016: Noxopharm Provides Update On Inaugural clinical Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Adamed Sp z oo, H2 2017

Pipeline by Astex Pharmaceuticals Inc, H2 2017

Pipeline by Bristol-Myers Squibb Company, H2 2017

Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Pipeline by Novartis AG, H2 2017

Pipeline by Noxopharm Ltd, H2 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Adamed Sp z oo

Astex Pharmaceuticals Inc

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd

Novartis AG

Noxopharm Ltd

Takeda Pharmaceutical Company Ltd

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Therapeutic Products under Development, Key Players in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Therapeutics, E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Pipeline Overview, E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Pipeline, E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Pipeline Assessment

select a license
Single User License
USD 3500 INR 249165
Site License
USD 7000 INR 498330
Corporate User License
USD 10500 INR 747495

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com